Octagam® 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases

Journal of Clinical Immunology

Volumn 24, Issue 3, 2004, Pages 309-314

  Ochs, Hans D ^a   Pinciaro, Paul J ^b   Berger, Melvin ^c   Kao, Neil ^d   Kishiyama, Jeffrey ^e   Kobayashi, Roger ^f   Shearer, William ^g   Skoda Smith, Suzanne ^h   Smits, William ⁱ   Stein, Mark ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Primaryimmune Services Inc   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d Allergic Disease and Asthma Center   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Allergic Disease Center   (United States)

^g TEXAS CHILDREN S HOSPITAL   (United States)

^h UNIVERSITY OF FLORIDA   (United States)

ⁱ Allerg Assoc of the Palm Beaches ^*

Author keywords

Clinical study; Efficacy; IgG; Immunoglobulins; Intravenous; Primary immunodeficiency diseases

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BACKACHE; CHILD; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; FEVER; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; IMMUNE DEFICIENCY; INFECTION; INFECTION RATE; INJECTION SITE; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; THORAX PAIN; TIME; UNITED STATES; METABOLISM; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; MALE; MIDDLE AGED;

EID: 3543141237     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:JOCI.0000025453.23817.3f     Document Type: Article

References (12)

1. Cooper MD, Lawton AR: Primary immunodeficiency diseases. In Harrison's Principles of Internal Medicine, AS Fauci, E Braunwald, KJ Isselbacher, Wilson JD, Kasper DL, Hauser SL, Longo DL, (eds). New York, McGraw-Hill, 1998, pp 1783-1791
2. Cunningham-Rundles C, Siegal FP, Smithwick EM, Lion-Boule A, Cunningham-Rundles S, O'Malley J, Barandun S, Good RA: Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Intern Med 101:435-439, 1984
3. Montanaro A, Pirofsky B: Prolonged interval high-dose intravenous immunoglobulin in patients with primary immunodeficiency states. Am J Med 76:67-72, 1984
4. Nolte MT, Pirofsky B, Gerritz GA, Golding B: Intravenous immunoglobulin therapy for antibody deficiency. Clin Exp Immunol 36:237-243, 1979
5. Stiehm ER: Human intravenous immunoglobulin in primary and secondary antibody deficiencies. Pediatr Infect Dis J 16:696-707, 1997
6. Yap PL: The viral safety of intravenous immune globulin. Clin Exp Immunol 104(Suppl 1):35-42, 1996
7. Piet MP, Chin S, Prince AM, Brotman B, Cundell AM, Horowítz B: The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation. Transfusion 30:591-598, 1990
8. Eibl MM, Wedgwood RJ: Intravenous immunoglobulin: A review. Immunodefic Rev 1(Suppl):1-42, 1989
9. Biesert L: Virus validation studies of immunoglobulin preparations. Clin Exp Rheumatol 14(Suppl 15):S47-S52, 1996
10. Department of Health and Human Services, Food and Drug Administration Center for Biologies Evaluation and Research: Blood Products Advisory Committee, 65th meeting, Washington, March 17, 2000. Washington, Miller Reporting Company, Inc
11. Brennan VM, Salome-Bentley NJ, Chapel HM: Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol 133:247-251, 2003
12. Eijkhout HW, Der-Meer JW, Kallenberg CG, Weening RS, van Dissel JT, Sanders LA, Strengers PF, Nienhuis H, Schellekens PT: The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med 135:165-174, 2001